New hope for tough leukemia: CAR t cell trial opens for adults

NCT ID NCT07361029

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new type of immunotherapy called CAR T cells for adults (ages 18-75) with a hard-to-treat blood cancer called acute lymphoblastic leukemia (ALL) that has come back or not responded to standard treatments. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer cells, and then giving them back. The main goal is to find the safest dose and understand side effects, while also checking if the treatment can help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • King Faisal Specialist Hospital and Research Center

    RECRUITING

    Riyadh, Riyadh Region, Saudi Arabia

    Contact Phone: •••-•••-•••• Email: •••••@•••••